Blog

Why Medical Device Companies Need to Develop Economic Evidence in the U.S.

Why Medical Device Companies Need to Develop Economic Evidence in the U.S. 150 150 Avalon Health Economics LLC

Although the U.S. lacks a centralized health technology evaluation agency, as many of the European countries maintain, in recent years there has been considerable pressure to control the rising costs of new biopharmaceuticals and medical devices.[1-5] After relatively slow growth in the 1960s, U.S. health care expenditures grew intensely in the decades between 1980 and…

read more

Reference Pricing for in vivo and in vitro Diagnostic Tests

Reference Pricing for in vivo and in vitro Diagnostic Tests 150 150 Avalon Health Economics LLC

Prices in health care vary widely even within the same local market and for similar tests and treatments. This reflects differences among providers in their ability and willingness to leverage bargaining power against private insurers. For their part, consumers and patients often have been indifferent to price since they have been well covered by insurance.…

read more

Purchasing Medical Innovation: The Implications for the Medical Device Industry

Purchasing Medical Innovation: The Implications for the Medical Device Industry 150 150 Avalon Health Economics LLC

In an earlier blog, we reviewed the recent book by one of Avalon’s directors, James Robinson. Robinson’s book, entitled “Purchasing Medical Innovation: The Right Technology, for the Right Patient, at the Right Price” seeks to unpack the often precarious relationships among medical device makers, the purchasers of those devices, the insurers, who are often the…

read more

Physician Shortages in the U.S.: Disentangling Myth, Folklore, and Fact

Physician Shortages in the U.S.: Disentangling Myth, Folklore, and Fact 150 150 Avalon Health Economics LLC

Much of the public media and even a substantial part of the medical literature operates on the assumption that there is a shortage of physicians in the U.S., including those specializing in primary care, intensive care, and surgery. One study, for example, estimated that the physician shortfall in the U.S. would reach 90,000 by 2025.[1]…

read more

Controlling the Costs of Clinical Laboratory Testing in Medical Practice

Controlling the Costs of Clinical Laboratory Testing in Medical Practice 150 150 Avalon Health Economics LLC

Today’s clinical laboratory can do much more than you think. Advances in molecular diagnostics, genetics and biomarkers have ushered in a new era of clinical laboratory capabilities. Along with these advances, however, are higher laboratory expenditures. The U.S. Medicare program spent $6.5 billion annually on laboratory in 2006. By 2010, the program was spending $8.2…

read more

Fad Diets and Nutrition: What’s all the Fuss about Gluten?

Fad Diets and Nutrition: What’s all the Fuss about Gluten? 150 150 Avalon Health Economics LLC

In recent years, the food industry has seen a boom in the “free from” category, including a myriad of ingredients such as high fructose corn syrup, artificial flavors, toxic pesticides, artificial hormones, antibiotics, and GMOs. One such product that has been particularly demonized recently is gluten. Celebrities from Miley Cyrus to former president Bill Clinton…

read more

The New Era of Cost Control in Healthcare: What Should you look for in a Health Economics and Outcomes Research Consultant?

The New Era of Cost Control in Healthcare: What Should you look for in a Health Economics and Outcomes Research Consultant? 150 150 Avalon Health Economics LLC

In recent years, there has been a small but measurable slowdown in the rate of increase in health expenditures, both here in the U.S. and abroad. The slowdown is largely attributable to a higher level of commitment on the part of payers to increase enrollee cost sharing and control access to high cost treatments.[1-3] If…

read more

Paying for Specialty Pharmaceuticals: The Case of Injectable Oncology Drugs

Paying for Specialty Pharmaceuticals: The Case of Injectable Oncology Drugs 150 150 Avalon Health Economics LLC

According to the American Cancer Society, the financial costs of cancer are high for both the person with cancer and for society as a whole. The National Institutes of Health (NIH) estimated the 2009 overall annual costs of cancer in the U.S. to be $216.6 billion, consisting of $86.6 billion in direct costs and $130…

read more

Integration of Novel Diagnostics into Clinical Practice

Integration of Novel Diagnostics into Clinical Practice 150 150 Avalon Health Economics LLC

Similar to drug and device markets, a critical part of the success of novel diagnostics is educating providers on clinical and therapeutic utility. However, unlike pharmaceutical drugs, the ordering of a diagnostic test does not necessarily imply a change in provider behavior or a change in treatment strategy. It’s a bit like whether a tree…

read more

The State of the Union and Innovation in Molecular Diagnostics

The State of the Union and Innovation in Molecular Diagnostics 150 150 Avalon Health Economics LLC

During the U.S. “State of the Union” address this past week, President Obama devoted some time to emphasizing the importance of “personalized medicine,” referring to the rapid pace of innovation and the high expectations for the role molecular diagnostics in the U.S. health care system: “I want the country that eliminated polio and mapped the…

read more
Loading...